Pseudomonas Aeruginosa Infection Treatment Market

SKU: DMHOS2668 | Last Updated On: Sep 21 2022 | Available Formats

>Pseudomonas Aeruginosa Infection Treatment Market Expected to reach a high CAGR of 6.5% during the forecast period 2022-2029:

Pseudomonas Aeruginosa Infection Treatment Market is segmented By Treatment (Monotherapy, Combination Therapy), By Drug Class (Aminoglycoside, Monobactam, Carbapenem, Cephalosporin, Others), By Route of Administration (Nasal, Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Pseudomonas Aeruginosa Infection Treatment Market Outlook

Pseudomonas aeruginosa infection treatment market was valued at USD 1.31 billion in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029). Pseudomonas Aeruginosa (also known as P. aeruginosa) is an important cause of gram-negative infection, especially in patients with compromised host defense mechanisms. Pseudomonas aeruginosa is a multidrug-resistant pathogen known for its intrinsically advanced antibiotic resistance mechanisms, its antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections (HAIs) such as ventilator-associated pneumonia and various sepsis syndromes. These bacteria frequently cause urinary tract infections (UTIs), lung infections, pneumonia, and chronic pain. People with a low immune system are highly prone to affect by this infection.

The incidence of Hospital Acquired Infections (HAIs) has increased in recent years. As P. aeruginosa infection is one of the common infections in a hospital facility, the chances of being diagnosed with P. aeruginosa infection are high. This has led to an increase in research and development to find the treatment for P. aeruginosa. Several drugs are in the pipeline phases for the treatment of this infection.

Pseudomonas Aeruginosa Infection Treatment Market Dynamics:

rising incidences of nosocomial infections associated with P. aeruginosa

The pseudomonas aeruginosa infection treatment market growth is majorly driven by the rising incidences of nosocomial infections associated with P. aeruginosa, rapidly growing antibacterial resistance, and increasing research & development of pseudomonas aeruginosa infection treatments.

The rise in the prevalence of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others, are expected to drive the growth of the global pseudomonas aeruginosa infection treatment market over the forecast period. There is a rise in the incidence of pseudomonas aeruginosa infections in intensive care which is projected to boost the demand for newer pseudomonas aeruginosa infection treatment drugs. As per the Centers for Disease Control and Prevention (CDC), about 51,000 healthcare-associated pseudomonas aeruginosa infections occur in the United States annually. Over 6,000 (13%) of these are multidrug-resistant, with around 400 deaths per year attributed to these infections. The growing mortality rate owing to hospital-acquired infection(HAIs) is caused due to P. aeruginosa bacteria, especially in immunocompromised hosts. About 35 % of healthcare-acquired infections cause respiratory system infections, urinary infections, gastrointestinal infections, and other disorders, which leads to a rise in the demand for pseudomonas aeruginosa treatment.

In addition, increasing the usage of antibiotics for the treatment of pseudomonas aeruginosa infection is also driving market growth. Owing to the increasing use of antibiotics for the treatment of P. aeruginosa infection, the emergence of antibiotic-resistant bacterial strains has this line of treatment almost ineffective. In this scenario, pharma companies are focused on developing a treatment approach for the same. This provides ample white space for players in the pseudomonas aeruginosa infection treatment market to capitalize on.

The rising investments and extensive research & development are boosting the development of novel therapies. The major players are investing heavily in R&D for non-antibiotic treatment options. Several pharma companies are testing novel compounds that bear chemical similarities with antibiotics. Increasing funding for research and development is expected to boost market growth. For instance, in November 2021, PlateletBio, a preclinical stage company that invested in developing a new approach to allogeneic cell therapies, raised $75.5 million in a Series B financing round to advance its pioneering approach to the field. The company is developing new allogeneic cell therapies based on platelet biology. Its lead candidate is in preclinical development for immune thrombocytopenia (ITP), an autoimmune disease. Also, in July 2022, Carmot Therapeutics, Inc., a clinical-stage biotechnology company announced to invest 160 million USD financing for drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer.

However, extended use of antibiotics leads to harmful effects on the patient, which is likely to hamper the market growth. However, as P. aeruginosa shows the ability of drug resistance, several drug developers, who have limited funds are dissuaded from the market.

Pseudomonas Aeruginosa Infection Treatment Market Segmentation:

Therapy segment for the highest share in global pseudomonas aeruginosa infection treatment market

The pseudomonas aeruginosa infection treatment market is classified by medication into monotherapy and combination therapy. Among these, the combination therapy segment accounted for the largest market share in the global pseudomonas aeruginosa infection treatment market in 2021. Combination therapy is used for the patient who has developed resistance property against monotherapy. During this therapy, a combination of different drugs is used to treat bacterial infections. The rise in drug resistance in monotherapy has increased the demand for combination therapy for the treatment of pseudomonas aeruginosa infection. As per the research, combination therapy showed promising results and the mortality was lower in patients receiving combination therapy, compared to monotherapy.  Also, the growth of combination therapy for the treatment of P. aeruginosa infection is due to its rapid onset of action, high bioavailability rate, cost-saving, and high efficiency. Hence, these factors are expected to boost the growth of the combination therapy segment.

Based on drug class, the global pseudomonas aeruginosa infection treatment market is segmented into cephalosporin, aminoglycoside, carbapenem, monobactam, and others Among these, the cephalosporin segment held the largest market share in 2019, owing to the increasing development of a new class of cephalosporin for the treatment of various P. aeruginosa infections by significant companies. A new cephalosporin (fifth-generation) was developed for the treatment of gram-negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. The launch of a new cephalosporin class of drugs is likely to boost the growth of the segment.

Based on the route of administration, the global pseudomonas aeruginosa infection treatment market has been segmented into oral, nasal, and intravenous. The intravenous segment is expected to dominate the global pseudomonas aeruginosa infection treatment market during the forecast period because most of the drugs available for the intravenous route as it gives rapid onset of action and high accuracy in dosing compared with other routes. Most physicians prefer the intravenous route for the administration of drugs, as in the intravenous route, the entire dose reaches the systemic circulation immediately with rapid onset of action against bacteria.

Pseudomonas Aeruginosa Infection Treatment Market

Metrics

Details

Market CAGR

6.5%

Segments Covered

By Treatment, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Pseudomonas Aeruginosa Infection Treatment Market Geographical Penetration:

North America is the dominating region during the forecast period.

North America region is dominating the global pseudomonas aeruginosa infection treatment market accounted for the largest market share in 2021, owing to rising incidences of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others. As per the the Centers for Disease Control (CDC) estimates that HAIs account for an estimated 1.7 million infections and 99,000 associated deaths each year. In addition, 32 percent of all healthcare-acquired infection are urinary tract infections and 22 percent are surgical site infections. According to the Provincial Infection Control Network of British Columbia, HAIs are a major patient safety issue and economic burden for the healthcare system.  In Canada, one in every nine hospital patients contracts a healthcare-associated infection. It is estimated that each year in Canada, there are more than 220,000 cases of HAI in Canada hospitals, resulting in at least 8,000 deaths. As Pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries. The U.S. and Canada have a well-developed health care system that encourages research and development for the treatment of these infections. These countries have a major presence of diverse global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Europe is the second-largest market for pseudomonas aeruginosa infection treatment in terms of market value, due to rising incidences of pseudomonas aeruginosa infection, the presence of major players, and the early adoption of new products. For instance, in Germany, about 22,000 to 33,000 people are suffering from pseudomonas aeruginosa infection.

The Asia-Pacific pseudomonas aeruginosa infection treatment market is expected to grow at the fastest growth rate over the forecast period. Developing countries such as China, India, and South Korea are expected to be lucrative markets over the forecast period, owing to growing awareness, increasing incidences of healthcare-associated pseudomonas aeruginosa infection, rapidly developing healthcare infrastructure, and high demand for advanced therapeutics. About 165,000 to 180,000 people in Australia suffer from hospital-acquired infections, as per a study, and of these, about 9,000 have pseudomonas aeruginosa infection.

Pseudomonas Aeruginosa Infection Treatment Market Competitive Landscape:

The global players are manufacturing the majority of the pseudomonas aeruginosa infection treatment drugs and therapies. Some of the key players which are contributing to the growth of the market include AbbVie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Co., Lupin Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Gilead Sciences Inc., Novartis AG, among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the pseudomonas aeruginosa infection treatment market globally. For instance

In April 2021, CARB-X funded up to 5.3 million USD to Phico therapeutics to develop an engineered bacteriophage drug to treat ventilator-associated pneumonia caused by drug-resistant pseudomonas aeruginosa.

In May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., launched generic erythromycin tablets in the USA. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin. The tables are available in sizes of 250 mg and 500 mg.

In September 2019, Armata Pharmaceuticals, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients.

In March 2019, Allergan received the U.S. FDA approval for the AVYCAZ treatment of complicated intra-abdominal infections (cIAI) and urinary tract infections (cUTI) in pediatric patients.

Frequently Asked Questions

What is the Projected CAGR value of the Pseudomonas Aeruginosa Infection Treatment Market?

Pseudomonas Aeruginosa Infection Treatment Market is expected to grow at a CAGR of 6.5% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Pseudomonas Aeruginosa Infection Treatment Market during 2022-2029

Which is the fastest growing region in the Pseudomonas Aeruginosa Infection Treatment Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period

Trending Topics

Infection Control Market

UV Infection Control Devices Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest